| scholarly article | Q13442814 |
| P50 | author | Roy W. Beck | Q88156417 |
| Kellee M Miller | Q88663907 | ||
| Diabetic Retinopathy Clinical Research Network | Q98806904 | ||
| Adam R Glassman | Q98807054 | ||
| Ingrid U. Scott | Q108861392 | ||
| Neil M. Bressler | Q112187433 | ||
| Susan B Bressler | Q114739669 | ||
| P2093 | author name string | Frederick L Ferris | |
| Lloyd Paul Aiello | |||
| Michael J Elman | |||
| Allison R Edwards | |||
| Cynthia R Stockdale | |||
| Scott M Friedman | |||
| Jennifer K Sun | |||
| P2860 | cites work | Vascular endothelial growth factor induces rapid phosphorylation of tight junction proteins occludin and zonula occluden 1. A potential mechanism for vascular permeability in diabetic retinopathy and tumors | Q78101810 |
| Intravitreal triamcinolone for refractory diabetic macular edema | Q31050662 | ||
| Macular grid photocoagulation after intravitreal triamcinolone acetonide for diffuse diabetic macular edema | Q33242783 | ||
| Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial | Q33249354 | ||
| Relationship between optical coherence tomography-measured central retinal thickness and visual acuity in diabetic macular edema | Q33264487 | ||
| Comparison of the modified Early Treatment Diabetic Retinopathy Study and mild macular grid laser photocoagulation strategies for diabetic macular edema | Q33281590 | ||
| A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema | Q33294185 | ||
| Intravitreal triamcinolone versus laser photocoagulation for persistent diabetic macular oedema | Q33329041 | ||
| A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema | Q33355710 | ||
| Progression of macular ischemia following intravitreal bevacizumab | Q33457392 | ||
| Primary End Point (Six Months) Results of the Ranibizumab for Edema of the mAcula in diabetes (READ-2) study | Q33495893 | ||
| Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders | Q34292807 | ||
| A computerized method of visual acuity testing: adaptation of the early treatment of diabetic retinopathy study testing protocol | Q44178716 | ||
| Intravitreal bevacizumab in active progressive proliferative diabetic retinopathy | Q46434222 | ||
| Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals | Q46847276 | ||
| Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy | Q46927800 | ||
| The 14-year incidence of visual loss in a diabetic population | Q47971799 | ||
| Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group | Q69874090 | ||
| Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Early Treatment Diabetic Retinopathy Study Research Group | Q70215925 | ||
| The Wisconsin epidemiologic study of diabetic retinopathy. IV. Diabetic macular edema | Q70741925 | ||
| Ten-year incidence of visual loss in a diabetic population | Q72006850 | ||
| P433 | issue | 6 | |
| P921 | main subject | laser | Q38867 |
| diabetic macular edema | Q18558081 | ||
| P304 | page(s) | 1064-1077.e35 | |
| P577 | publication date | 2010-04-28 | |
| P1433 | published in | Ophthalmology | Q7098109 |
| P1476 | title | Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema | |
| P478 | volume | 117 |
| Q33956443 | 12-month results of the standardised combination therapy for diabetic macular oedema: intravitreal bevacizumab and navigated retinal photocoagulation |
| Q34200374 | 25th RCOphth Congress, President's Session paper: 25 years of progress in medical retina. |
| Q58715488 | 3-year-data of combined navigated laser photocoagulation (Navilas) and intravitreal ranibizumab compared to ranibizumab monotherapy in DME patients |
| Q94461905 | A 12-month prospective study to evaluate the efficacy of using the treat-and-extend regimen with intravitreal aflibercept as a Second-Line Treatment for Diabetic Macular Oedema (the TADI Study) |
| Q37183169 | A Crossover Design for Comparative Efficacy: A 36-Week Randomized Trial of Bevacizumab and Ranibizumab for Diabetic Macular Edema |
| Q37731896 | A Quantitative Approach to Predict Differential Effects of Anti-VEGF Treatment on Diffuse and Focal Leakage in Patients with Diabetic Macular Edema: A Pilot Study |
| Q33740152 | A Review of Ranibizumab for the Treatment of Diabetic Retinopathy |
| Q57062995 | A Smartphone-Based Tool for Rapid, Portable, and Automated Wide-Field Retinal Imaging |
| Q51503400 | A multicenter, 12-month randomized study comparing dexamethasone intravitreal implant with ranibizumab in patients with diabetic macular edema. |
| Q34632358 | A multicentre phase III randomised controlled single-masked clinical trial evaluating the clinical efficacy and safety of light-masks at preventing dark-adaptation in the treatment of early diabetic macular oedema (CLEOPATRA): study protocol for a r |
| Q35809696 | A prospective randomised controlled clinical trial comparing a combination of repeated intravitreal Ozurdex and macular laser therapy versus macular laser only in centre-involving diabetic macular oedema (OZLASE study). |
| Q27008325 | A review of therapies for diabetic macular oedema and rationale for combination therapy |
| Q34325559 | A safety audit of the first 10 000 intravitreal ranibizumab injections performed by nurse practitioners |
| Q34444227 | A three-year follow-up of intravitreal triamcinolone acetonide injection and macular laser photocoagulation for diffuse diabetic macular edema |
| Q90371390 | ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY AND RISK OF TRACTION RETINAL DETACHMENT IN EYES WITH PROLIFERATIVE DIABETIC RETINOPATHY: Pooled Analysis of Five DRCR Retina Network Randomized Clinical Trials |
| Q50104573 | ASSOCIATION BETWEEN EARLY ANATOMIC RESPONSE TO ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY AND LONG-TERM OUTCOME IN DIABETIC MACULAR EDEMA: AN INDEPENDENT ANALYSIS OF PROTOCOL I STUDY DATA. |
| Q35797079 | Action on AMD. Optimising patient management: act now to ensure current and continual delivery of best possible patient care |
| Q38088818 | Advances in our understanding of diabetic retinopathy. |
| Q35649512 | Advances in the management of diabetic macular oedema based on evidence from the Diabetic Retinopathy Clinical Research Network |
| Q87281953 | Advances in the treatment of diabetic retinopathy |
| Q55417802 | Aflibercept for diabetic macular oedema: a Meta-analysis of randomized controlled trials. |
| Q38747162 | Aflibercept for the treatment of diabetic macular edema |
| Q38937864 | Aflibercept in diabetic macular edema: evaluating efficacy as a primary and secondary therapeutic option |
| Q35943499 | Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial |
| Q35575496 | Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema |
| Q36013973 | Aflibercept: A Review of Its Use in the Management of Diabetic Eye Complications |
| Q27025635 | Alternative pathways in the development of diabetic retinopathy: the renin-angiotensin and kallikrein-kinin systems |
| Q60930641 | An efficacy comparison of anti-vascular growth factor agents and laser photocoagulation in diabetic macular edema: a network meta-analysis incorporating individual patient-level data |
| Q34109862 | An open-label, one-year, noncomparative study to evaluate the safety and tolerability of intravitreal pegaptanib sodium in patients with diabetic macular edema |
| Q99238749 | Analysis of Funding Source and Spin in the Reporting of Studies of Intravitreal Corticosteroid Therapy for Diabetic Macular Edema: A Systematic Review |
| Q52646207 | Angiogenic and Immunologic Proteins Identified by Deep Proteomic Profiling of Human Retinal and Choroidal Vascular Endothelial Cells: Potential Targets for New Biologic Drugs. |
| Q39455385 | Animal models of ocular angiogenesis: from development to pathologies |
| Q93518908 | Answer: Can you identify this condition? |
| Q64083037 | Anti-Hexokinase 1 Antibody as a Novel Serum Biomarker of a Subgroup of Diabetic Macular Edema |
| Q91842594 | Anti-VEGF Treatment of Diabetic Macular Edema: Two-Year Visual Outcomes in Routine Clinical Practice |
| Q35151008 | Anti-VEGF for the management of diabetic macular edema |
| Q38219571 | Anti-VEGF therapy for diabetic macular edema |
| Q36155647 | Anti-Vascular Endothelial Growth Factor Comparative Effectiveness Trial for Diabetic Macular Edema: Additional Efficacy Post Hoc Analyses of a Randomized Clinical Trial |
| Q24193083 | Anti-vascular endothelial growth factor for diabetic macular oedema |
| Q57456682 | Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis |
| Q34558187 | Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis. |
| Q35064343 | Anti-vascular endothelial growth factor therapy for diabetic macular edema |
| Q64880138 | Anti-vascular endothelial growth factor treatment for retinal conditions: a systematic review and meta-analysis. |
| Q37241685 | Anti-vascular endothelial growth factor treatment in diabetic macular edema |
| Q34295974 | Antiangiogenic therapy for ischemic retinopathies |
| Q24202071 | Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema |
| Q51742251 | Aqueous Humor Cytokine Levels and Anatomic Response to Intravitreal Ranibizumab in Diabetic Macular Edema. |
| Q34024289 | Are individuals with diabetes seeing better?: a long-term epidemiological perspective |
| Q90205887 | Assessment of Patient Pain Experience During Intravitreal Ranibizumab and Aflibercept Injection |
| Q52679452 | Association of Changes in Macular Perfusion With Ranibizumab Treatment for Diabetic Macular Edema: A Subanalysis of the RESTORE (Extension) Study. |
| Q41895064 | Association of outer retinal layer morphology with visual acuity in patients with retinal vein occlusion: SCORE Study Report 13. |
| Q47876612 | Automated quantitative characterisation of retinal vascular leakage and microaneurysms in ultra-widefield fluorescein angiography |
| Q34942261 | Baseline central macular thickness predicts the need for retreatment with intravitreal triamcinolone plus laser photocoagulation for diabetic macular edema |
| Q58777290 | Baseline morphological characteristics as predictors of final visual acuity in patients with branch retinal vein occlusions: MARVEL report no. 3 |
| Q42602540 | Baseline visual acuity strongly predicts visual acuity gain in patients with diabetic macular edema following anti-vascular endothelial growth factor treatment across trials |
| Q34675149 | Bevacizumab for the management of diabetic macular edema |
| Q24186434 | Blood pressure control for diabetic retinopathy |
| Q36501143 | Blood pressure, vessel caliber, and retinal thickness in diabetes |
| Q91575951 | CHANGES IN DIABETIC RETINOPATHY SEVERITY WHEN TREATING DIABETIC MACULAR EDEMA WITH RANIBIZUMAB: DRCR.net Protocol I 5-Year Report |
| Q49558328 | CHANGES IN PLASMA VASCULAR ENDOTHELIAL GROWTH FACTOR LEVEL AFTER INTRAVITREAL INJECTION OF BEVACIZUMAB, AFLIBERCEPT, OR RANIBIZUMAB FOR DIABETIC MACULAR EDEMA. |
| Q30491050 | CLINICAL EVIDENCE OF THE MULTIFACTORIAL NATURE OF DIABETIC MACULAR EDEMA. |
| Q64091553 | Cataract in diabetes mellitus |
| Q58792661 | Cataract surgery in diabetes mellitus: A systematic review |
| Q38817006 | Change in Diabetic Retinopathy Through 2 Years: Secondary Analysis of a Randomized Clinical Trial Comparing Aflibercept, Bevacizumab, and Ranibizumab |
| Q55176159 | Changes in Blood Pressure and Urine Albumin-Creatinine Ratio in a Randomized Clinical Trial Comparing Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema. |
| Q35346991 | Chemokine mediated monocyte trafficking into the retina: role of inflammation in alteration of the blood-retinal barrier in diabetic retinopathy |
| Q57652338 | Choroidal thickness changes stratified by outcome in real-world treatment of diabetic macular edema |
| Q36313962 | Clinical Characteristics of Patients with Newly Diagnosed Diabetic Macular Edema in Turkey: A Real-Life Registry Study-TURK-DEM. |
| Q26825365 | Clinical development of new treatments for diabetic macular oedema |
| Q31146864 | Clinical trials on corticosteroids for diabetic macular edema |
| Q34139793 | Clinical utilization of anti-vascular endothelial growth-factor agents and patient monitoring in retinal vein occlusion and diabetic macular edema |
| Q36324841 | Combination of Anti-VEGF and Laser Photocoagulation for Diabetic Macular Edema: A Review |
| Q36313966 | Combination of Navigated Macular Laser Photocoagulation and Anti-VEGF Therapy: Precise Treatment for Macular Edema under Dry Retinal Conditions |
| Q41250047 | Combined Intravitreal Dexamethasone Implant And Micropulse Yellow Laser For Treatment Of Anti-VEGF Resistant Diabetic Macular Edema |
| Q35067115 | Combined therapy for diabetic macular edema |
| Q42353631 | Comorbidity and health care visit burden in working-age commercially insured patients with diabetic macular edema |
| Q41494022 | Comparative Effectiveness Trial for Diabetic Macular Edema: Three Comparisons for the Price of 1 Study From the Diabetic Retinopathy Clinical Research Network |
| Q34775904 | Comparative evaluation of combined navigated laser photocoagulation and intravitreal ranibizumab in the treatment of diabetic macular edema |
| Q35684594 | Comparing the effectiveness and costs of Bevacizumab to Ranibizumab in patients with Diabetic Macular Edema: a randomized clinical trial (the BRDME study). |
| Q55362259 | Comparison of Intravitreal Aflibercept and Ranibizumab following Initial Treatment with Ranibizumab in Persistent Diabetic Macular Edema. |
| Q49385210 | Comparison of Intravitreal Bevacizumab and Intravitreal Diclofenac in the Treatment of Diabetic Macular Edema: a 6-month Follow-up. |
| Q34011604 | Comparison of grid laser, intravitreal triamcinolone, and intravitreal bevacizumab in the treatment of diffuse diabetic macular edema. |
| Q37623605 | Comparison of time- and spectral-domain optical coherence tomography in management of diabetic macular edema |
| Q38261106 | Complications of intravitreal injections in patients with diabetes |
| Q36490459 | Complications of intravitreal triamcinolone acetonide for macular edema and predictive factors for intraocular pressure elevation |
| Q36079348 | Conversion to aflibercept for diabetic macular edema unresponsive to ranibizumab or bevacizumab |
| Q92126316 | Correlation of multicolor images and conventional color fundus photographs with foveal autofluorescence patterns in diabetic macular edema |
| Q36409906 | Corticosteroid Treatment in Diabetic Macular Edema |
| Q92671027 | Corticosteroids for Diabetic Macular Edema |
| Q52615212 | Cost Evaluation of Early Vitrectomy versus Panretinal Photocoagulation and Intravitreal Ranibizumab for Proliferative Diabetic Retinopathy. |
| Q39593443 | Cost Evaluation of Panretinal Photocoagulation versus Intravitreal Ranibizumab for Proliferative Diabetic Retinopathy. |
| Q36095304 | Cost of diabetic retinopathy and macular oedema in a population, an eight year follow up |
| Q99563463 | Cost-consequence analysis of extended loading dose of anti-VEGF treatment in diabetic macular edema patients |
| Q34232330 | Cost-effectiveness analysis of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema |
| Q38376964 | Cost-effectiveness of Intravitreous Ranibizumab Compared With Panretinal Photocoagulation for Proliferative Diabetic Retinopathy: Secondary Analysis From a Diabetic Retinopathy Clinical Research Network Randomized Clinical Trial. |
| Q60913080 | Cost-effectiveness of fluocinolone acetonide implant (ILUVIEN®) in UK patients with chronic diabetic macular oedema considered insufficiently responsive to available therapies |
| Q31049802 | Cost-effectiveness of ranibizumab in treatment of diabetic macular oedema (DME) causing visual impairment: evidence from the RESTORE trial |
| Q33606611 | Cost-effectiveness of treatment of diabetic macular edema |
| Q34705556 | Cost-effectiveness of various interventions for newly diagnosed diabetic macular edema |
| Q34803171 | Critical appraisal of ranibizumab in the treatment of diabetic macular edema |
| Q37801912 | Current approaches to the management of diabetic retinopathy and diabetic macular oedema |
| Q38010064 | Current epidemiology of diabetic retinopathy and diabetic macular edema |
| Q35650268 | Current intravitreal pharmacologic therapies for diabetic macular edema |
| Q59797373 | Current management of diabetic tractional retinal detachments |
| Q28082383 | Current perspectives on ranibizumab |
| Q35023708 | Current status in diabetic macular edema treatments |
| Q34606190 | Current treatments in diabetic macular oedema: systematic review and meta-analysis |
| Q92533203 | Cytokine and Chemokine Profile Changes in Patients After Intravitreal Conbercept Injection for Diabetic Macular Edema |
| Q90056412 | Deep learning-based single-shot prediction of differential effects of anti-VEGF treatment in patients with diabetic macular edema |
| Q38815223 | Delivery of steroids into the eye for the treatment of macular edema |
| Q31155420 | Demographics of patients receiving Intravitreal anti-VEGF treatment in real-world practice: healthcare research data versus randomized controlled trials |
| Q49722136 | Detailed analysis of retinal morphology in patients with diabetic macular edema (DME) randomized to ranibizumab or triamcinolone treatment - reply to the letter to the editor. |
| Q49199328 | Detailed analysis of retinal morphology in patients with diabetic macular edema (DME) randomized to ranibizumab or triamcinolone treatment. |
| Q37973348 | Development of Anti-VEGF Therapies for Intraocular Use: A Guide for Clinicians |
| Q35854075 | Dexamethasone implant in diabetic macular edema in real-life situations |
| Q35828114 | Dexamethasone intravitreal implant in previously treated patients with diabetic macular edema: subgroup analysis of the MEAD study. |
| Q28070894 | Diabetic Macular Edema Pathophysiology: Vasogenic versus Inflammatory |
| Q38731129 | Diabetic Macular Edema at the time of Cataract Surgery trial: a prospective, randomized clinical trial of intravitreous bevacizumab versus triamcinolone in patients with diabetic macular oedema at the time of cataract surgery - preliminary 6 month r |
| Q64980448 | Diabetic Macular Edema: Is Your Patient Going Blind? |
| Q45072634 | Diabetic Microvascular Disease: An Endocrine Society Scientific Statement |
| Q95641816 | Diabetic Population-Based Model to Estimate Impact of Ranibizumab on Diabetic Retinopathy Severity in Patients with Diabetic Macular Edema |
| Q37477129 | Diabetic Retinopathy Clinical Practice Guidelines: Customized for Iranian Population |
| Q38616344 | Diabetic Retinopathy and Diabetic Macular Edema |
| Q34551730 | Diabetic Retinopathy: A Position Statement by the American Diabetes Association. |
| Q55711452 | Diabetic Retinopathy: Pathophysiology and Treatments. |
| Q31146850 | Diabetic macular edema: Current management 2013 |
| Q59797366 | Diabetic macular edema: Evidence-based management |
| Q30415630 | Diabetic macular edema: New promising therapies |
| Q37985854 | Diabetic macular edema: current and emerging therapies |
| Q26745914 | Diabetic macular edema: it is more than just VEGF |
| Q34091784 | Diabetic macular edema: new trends in management |
| Q34185374 | Diabetic macular edema: therapeutic options |
| Q36096676 | Diabetic macular oedema |
| Q64239313 | Diabetic macular oedema and diode subthreshold micropulse laser (DIAMONDS): study protocol for a randomised controlled trial |
| Q47310979 | Diabetic macular oedema treated with intravitreal anti-vascular endothelial growth factor - 2-4 years follow-up of visual acuity and retinal thickness in 566 patients following Danish national guidelines |
| Q30101045 | Diabetic macular oedema: evidence-based treatment recommendations for Asian countries. |
| Q36018006 | Diabetic macular oedema: pathophysiology, management challenges and treatment resistance |
| Q33640419 | Diabetic maculopathy. Diagnosis and treatment |
| Q33910631 | Diabetic retinopathy (treatment) |
| Q50751871 | Diabetic retinopathy and OCT angiography: clinical findings and future perspectives. |
| Q34607862 | Diabetic retinopathy and VEGF. |
| Q96172012 | Diabetic retinopathy and diabetic macular oedema pathways and management: UK Consensus Working Group |
| Q34790721 | Diabetic retinopathy in sub-Saharan Africa: meeting the challenges of an emerging epidemic |
| Q88636150 | Diabetic retinopathy, an overview |
| Q39445950 | Diabetic retinopathy: current understanding, mechanisms, and treatment strategies |
| Q38682902 | Diabetic retinopathy: global prevalence, major risk factors, screening practices and public health challenges: a review |
| Q35975239 | Diabetic retinopathy: intravitreal vascular endothelial growth factor inhibitors for diabetic macular oedema |
| Q38199730 | Diabetic retinopathy: loss of neuroretinal adaptation to the diabetic metabolic environment |
| Q34498235 | Diabetic retinopathy: pathogenesis, clinical grading, management and future developments |
| Q42672190 | Diabetic retinopathy: research to clinical practice |
| Q35981628 | Diagnosis, treatment and monitoring of diabetic eye control |
| Q37733102 | Dietary hyperglycemia, glycemic index and metabolic retinal diseases |
| Q92701923 | Do Genomic Factors Play a Role in Diabetic Retinopathy? |
| Q37953969 | Drug safety evaluation of intravitreal triamcinolone acetonide |
| Q30490903 | EFFECT OF AN INTRAVITREAL DEXAMETHASONE IMPLANT ON DIABETIC MACULAR EDEMA AFTER CATARACT SURGERY. |
| Q52690258 | EFFICACY AND SAFETY OUTCOMES OF INTRAVITREAL AFLIBERCEPT FOCUSING ON PATIENTS WITH DIABETIC MACULAR EDEMA FROM JAPAN. |
| Q33878122 | Economic considerations of macular edema therapies |
| Q45305404 | Effect of Adding Dexamethasone to Continued Ranibizumab Treatment in Patients With Persistent Diabetic Macular Edema: A DRCR Network Phase 2 Randomized Clinical Trial |
| Q91626896 | Effect of Initial Management With Aflibercept vs Laser Photocoagulation vs Observation on Vision Loss Among Patients With Diabetic Macular Edema Involving the Center of the Macula and Good Visual Acuity: A Randomized Clinical Trial |
| Q35647107 | Effect of anti-vascular endothelial growth factor therapy on choroidal thickness in diabetic macular edema |
| Q33568545 | Effect of initial retinal thickness on outcome of intravitreal bevacizumab therapy for diabetic macular edema |
| Q34062356 | Effect of intravitreal bevacizumab on diabetic macular edema with hard exudates |
| Q93184605 | Effect of intravitreal dexamethasone solution on the reduction of macular thickness in pseudophakic diabetic patients in a public hospital in Brazil: a randomized clinical trial |
| Q36161138 | Effect of leaking perifoveal microaneurysms on resolution of diabetic macular edema treated by combination therapy using anti-vascular endothelial growth factor and short pulse focal/grid laser photocoagulation |
| Q37776148 | Effect of systemic medications on onset and progression of diabetic retinopathy |
| Q93131685 | Effectiveness of Multimodal imaging for the Evaluation of Retinal oedema And new vesseLs in Diabetic retinopathy (EMERALD) |
| Q89002608 | Effectiveness of the Dexamethasone Intravitreal Implant for Treatment of Patients with Diabetic Macular Oedema |
| Q58384543 | Effects of Fenofibric Acid on Diabetic Macular Edema: The MacuFen study |
| Q91976476 | Effects of subthreshold diode micropulse laser photocoagulation on treating patients with refractory diabetic macular edema |
| Q36949135 | Efficacy and Safety of a Dexamethasone Implant in Patients with Diabetic Macular Edema at Tertiary Centers in Korea. |
| Q89736391 | Efficacy and safety of Suprachoroidal Triamcinolone Acetonide in cases of resistant diabetic Macular Edema |
| Q37523465 | Efficacy and safety of widely used treatments for macular oedema secondary to retinal vein occlusion: a systematic review |
| Q33910289 | Efficacy of anti-VEGF and laser photocoagulation in the treatment of visual impairment due to diabetic macular edema: a systematic review and network meta-analysis |
| Q98163583 | Efficacy of combining intravitreal injections of ranibizumab with micropulse diode laser versus intravitreal injections of ranibizumab alone in diabetic macular edema (ReCaLL): a single center, randomised, controlled, non-inferiority clinical trial |
| Q33912485 | Efficiency and safety of laser photocoagulation with or without intravitreal ranibizumab for treatment of diabetic macular edema: a systematic review and Meta-analysis |
| Q37153890 | Electroretinographic evaluations of retinal function before, just after, and after intravitreal injections |
| Q90046873 | Emerging Insights and Interventions for Diabetic Retinopathy |
| Q58907881 | Emerging pharmacotherapies for diabetic macular edema |
| Q37879167 | Endophthalmitis following intravitreal anti-vascular endothelial growth factor injections for neovascular age-related macular degeneration |
| Q26827206 | Endothelial progenitor cells in diabetic retinopathy |
| Q41791333 | Enhanced oxygen saturation in optic nerve head of non-human primate eyes following the intravitreal injection of NCX 434, an innovative nitric oxide-donating glucocorticoid |
| Q26775552 | Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss |
| Q55270455 | Evaluation of Navigated Laser Photocoagulation (Navilas 577+) for the Treatment of Refractory Diabetic Macular Edema. |
| Q34158304 | Evaluation of masking study participants to intravitreal injections in a randomized clinical trial |
| Q100455041 | Evaluation of real-world early response of DMO to aflibercept therapy to inform future clinical trial design of novel investigational agents |
| Q90479193 | Evaluation of systemic risk factors in different optical coherence tomographic patterns of diabetic macular edema |
| Q89250688 | Evaluation of the effect of combined intravitreal ranibizumab injection and sub-tenon steroid injection in the treatment of resistant diabetic macular edema |
| Q36242390 | Evidence-Based Treatment of Diabetic Macular Edema |
| Q36152543 | Evidence-Based Treatment of Diabetic Retinopathy |
| Q28075473 | Evidence-based review of diabetic macular edema management: Consensus statement on Indian treatment guidelines |
| Q47729194 | Evolution of Intravitreal Therapy for Retinal Diseases - From CMV to CNV: The LXXIV Edward Jackson Memorial Lecture |
| Q88566503 | Evolution of intravitreal therapy for retinal and macular disorders |
| Q35067102 | Evolving strategies in the management of diabetic retinopathy |
| Q33860902 | Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema |
| Q34170485 | Exploratory analysis of the effect of intravitreal ranibizumab or triamcinolone on worsening of diabetic retinopathy in a randomized clinical trial |
| Q92883177 | Expression of vascular infarction-related molecules after anti-vascular endothelium growth factor treatment for diabetic macular edema |
| Q34263727 | Factors affecting reading speed in patients with diabetic macular edema treated with laser photocoagulation |
| Q35050082 | Factors affecting visual outcomes in patients with diabetic macular edema treated with ranibizumab |
| Q34410772 | Factors associated with changes in visual acuity and central subfield thickness at 1 year after treatment for diabetic macular edema with ranibizumab |
| Q92265948 | Factors influencing clinical outcomes in patients with diabetic macular edema treated with intravitreal ranibizumab: comparison between responder and non-responder cases |
| Q33759212 | Fellow eye effect of unilateral intravitreal bevacizumab injection in eyes with diabetic macular edema |
| Q30248492 | Fenofibrate and Diabetic Retinopathy |
| Q35902351 | Five-Year Outcomes of Ranibizumab With Prompt or Deferred Laser Versus Laser or Triamcinolone Plus Deferred Ranibizumab for Diabetic Macular Edema |
| Q33903781 | Five-year visual outcome following laser photocoagulation of diabetic macular oedema |
| Q41236033 | Fluocinolone acetonide and its potential in the treatment of chronic diabetic macular edema |
| Q34758061 | Fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema |
| Q35054244 | From scientific evidence to clinical practice: treatment protocols for diabetic macular edema |
| Q35596976 | Fully automatic software for retinal thickness in eyes with diabetic macular edema from images acquired by cirrus and spectralis systems |
| Q35935835 | Future opportunities in diabetic retinopathy research |
| Q37954532 | Gene transfer for ocular neovascularization and macular edema |
| Q91729475 | Glucocorticoid Receptor Transactivation Is Required for Glucocorticoid-Induced Ocular Hypertension and Glaucoma |
| Q47552785 | Glucocorticoid receptor GRβ regulates glucocorticoid-induced ocular hypertension in mice |
| Q34018552 | Green or yellow laser treatment for diabetic macular edema: exploratory assessment within the Diabetic Retinopathy Clinical Research Network |
| Q64069710 | Healthcare Utilization and Treatment Patterns in Diabetic Macular Edema in Korea: a Retrospective Chart Review |
| Q93023525 | How to manage patients with center-involving diabetic macular edema and good visual acuity? An answer to a common clinical question |
| Q35220996 | Human chorioretinal layer thicknesses measured in macula-wide, high-resolution histologic sections |
| Q36702382 | Hydroxyl PAMAM dendrimer-based gene vectors for transgene delivery to human retinal pigment epithelial cells |
| Q92824659 | Hyperreflective Foci in the Outer Retinal Layers as a Predictor of the Functional Efficacy of Ranibizumab for Diabetic Macular Edema |
| Q38614087 | Hypoxia and Dark Adaptation in Diabetic Retinopathy: Interactions, Consequences, and Therapy |
| Q34624034 | Imaging retinal pigment epithelial proliferation secondary to PASCAL photocoagulation in vivo by polarization-sensitive optical coherence tomography |
| Q55201911 | Impact of Baseline Central Retinal Thickness on Outcomes in the VIVID-DME and VISTA-DME Studies. |
| Q47428173 | Impact of baseline Diabetic Retinopathy Severity Scale scores on visual outcomes in the VIVID-DME and VISTA-DME studies |
| Q89822031 | Impact of manual correction over automated segmentation of spectral domain optical coherence tomography |
| Q35083575 | Importance of 3-D image reconstruction of spectral-domain OCT on outcome of grid laser photocoagulation for diffuse diabetic macular edema |
| Q34648669 | Indications for intravitreal bevacizumab in ibadan, sub-saharan Africa |
| Q37884176 | Inflammation in diabetic retinopathy |
| Q58095266 | Inflammatory mediators in the vitreal reflux of patients with diabetic macular edema |
| Q37744827 | Inhibition of Stat3 by a Small Molecule Inhibitor Slows Vision Loss in a Rat Model of Diabetic Retinopathy |
| Q34792137 | Injection frequency and response to bevacizumab monotherapy for diabetic macular oedema (BOLT Report 5). |
| Q41194130 | Intracellular delivery of dendrimer triamcinolone acetonide conjugates into microglial and human retinal pigment epithelial cells |
| Q36622491 | Intraocular pressure elevation after intravitreal triamcinolone acetonide injection: a Meta-analysis |
| Q91722691 | Intraocular pressure elevation after subtenon triamcinolone acetonide injection; Multicentre retrospective cohort study in Japan |
| Q30681823 | Intravitreal AAV2.COMP-Ang1 Prevents Neurovascular Degeneration in a Murine Model of Diabetic Retinopathy |
| Q36173627 | Intravitreal Conbercept Injection with and without Grid Laser Photocoagulation in the Treatment of Diffuse Diabetic Macular Edema in Real-Life Clinical Practice |
| Q37287831 | Intravitreal Corticosteroids in the Management of Diabetic Macular Edema |
| Q35465478 | Intravitreal Ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: 5-year randomized trial results |
| Q36764757 | Intravitreal bevacizumab for the treatment of nonarteritic anterior ischemic optic neuropathy: a prospective trial |
| Q41360622 | Intravitreal bevacizumab injection alone or combined with triamcinolone versus macular photocoagulation in bilateral diabetic macular edema; application of bivariate generalized linear mixed model with asymmetric random effects in a subgroup of a cl |
| Q26782198 | Intravitreal corticosteroids in diabetic macular edema: Pharmacokinetic considerations |
| Q34152161 | Intravitreal dexamethasone implant in patients with persistent diabetic macular edema |
| Q87411519 | Intravitreal diclofenac versus intravitreal bevacizumab in naive diabetic macular edema: a randomized double-masked clinical trial |
| Q90728459 | Intravitreal diclofenac versus intravitreal bevacizumab in persistent diabetic macular edema: Anatomical and functional outcome |
| Q89370307 | Intravitreal injection of methotrexate in persistent diabetic macular edema: a 6-month follow-up study |
| Q45166553 | Intravitreal injection of triamcinolone acetonide into healthy rabbit eyes alters retinal function and morphology |
| Q38053198 | Intravitreal injections: a review of the evidence for best practice |
| Q36468115 | Intravitreal pegaptanib sodium (Macugen®) for treatment of diabetic macular oedema: a morphologic and functional study. |
| Q34282654 | Intravitreal ranibizumab (lucentis) for the treatment of diabetic macular edema: a systematic review and meta-analysis of randomized clinical control trials |
| Q31100308 | Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results |
| Q35126845 | Intravitreal ranibizumab for subfoveal choroidal neovascularization from age-related macular degeneration with combined severe diabetic retinopathy |
| Q36951178 | Intravitreal triamcinolone acetonide: a "real world" analysis of visual acuity, pressure and outcomes |
| Q33841803 | Intravitreal versus sub-tenon posterior triamcinolone injection in bilateral diffuse diabetic macular edema |
| Q58762930 | Investigating the Fractal Dimension of the Foveal Microvasculature in Relation to the Morphology of the Foveal Avascular Zone and to the Macular Circulation in Patients With Type 2 Diabetes Mellitus |
| Q39699517 | Kernel regression based segmentation of optical coherence tomography images with diabetic macular edema. |
| Q35631284 | Kinetics of central macular thickness reduction in patients with macular edema after intravitreal drug therapy |
| Q35353446 | Laser-based strategies to treat diabetic macular edema: history and new promising therapies |
| Q42725230 | Lecithin-Bound Iodine Prevents Disruption of Tight Junctions of Retinal Pigment Epithelial Cells under Hypoxic Stress |
| Q28292764 | Long-term effectiveness of ranibizumab for age-related macular degeneration and diabetic macular edema |
| Q87434308 | Long-term effectiveness of vitrectomy in diabetic cystoid macular edema |
| Q57288658 | Long-term efficacy and duration of action of dexamethasone implant, in vitrectomised and non-vitrectomised eyes with persistent diabetic macular oedema |
| Q35649482 | Long-term follow-up of intravitreal bevacizumab in retinal arterial macroaneurysm: a case report |
| Q89710210 | Long-term results of a single injection of intravitreal dexamethasone as initial therapy in diabetic macular edema |
| Q57920483 | Lp-PLA2 activity is associated with increased risk of diabetic retinopathy: a longitudinal disease progression study |
| Q48579709 | Management of diabetic macular edema in Japan: a review and expert opinion. |
| Q62493181 | Management of diabetic retinopathy |
| Q35909406 | Management of retinal vascular diseases: a patient-centric approach |
| Q34000861 | Managing diabetic macular edema: The leading cause of diabetes blindness |
| Q39009395 | Mechanistic Insights into Pathological Changes in the Diabetic Retina: Implications for Targeting Diabetic Retinopathy |
| Q33855386 | Medical management of diabetic retinopathy: fenofibrate and ACCORD Eye studies |
| Q96950831 | Microperimetry and mfERG as functional measurements in diabetic macular oedema undergoing intravitreal ranibizumab treatment |
| Q37879581 | Microvascular modifications in diabetic retinopathy |
| Q39867113 | Modelling the cost-effectiveness of adopting risk-stratified approaches to extended screening intervals in the national diabetic retinopathy screening programme in Scotland. |
| Q57183608 | Molecular Mechanisms Mediating Diabetic Retinal Neurodegeneration: Potential Research Avenues and Therapeutic Targets |
| Q36296789 | Molecular pathogenesis of retinal and choroidal vascular diseases |
| Q37457142 | Month-6 primary outcomes of the READ-3 study (Ranibizumab for Edema of the mAcula in Diabetes-Protocol 3 with high dose). |
| Q28078199 | Moving Past Anti-VEGF: Novel Therapies for Treating Diabetic Retinopathy |
| Q34560679 | Navigated macular laser decreases retreatment rate for diabetic macular edema: a comparison with conventional macular laser |
| Q38050159 | Neuropeptides and diabetic retinopathy |
| Q26765468 | New Diagnostic and Therapeutic Approaches for Preventing the Progression of Diabetic Retinopathy |
| Q33583037 | New Therapeutic Approaches in Diabetic Retinopathy |
| Q26853239 | New approaches for the treatment of diabetic macular oedema: recommendations by an expert panel |
| Q33608021 | Noninvasive Retinal Markers in Diabetic Retinopathy: Advancing from Bench towards Bedside |
| Q35751912 | Novel Therapies in Development for Diabetic Macular Edema |
| Q34313113 | Novel atypical PKC inhibitors prevent vascular endothelial growth factor-induced blood-retinal barrier dysfunction |
| Q27002622 | Novel pharmacotherapies in diabetic retinopathy |
| Q28066675 | Novel pharmacotherapies in diabetic retinopathy: Current status and what's in the horizon? |
| Q49380314 | Novel therapeutic targets in diabetic macular edema: Beyond VEGF. |
| Q36217864 | OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY FEATURES OF DIABETIC RETINOPATHY. |
| Q35049903 | Ocular complications of diabetes mellitus |
| Q38018840 | Ophthalmic drug discovery: novel targets and mechanisms for retinal diseases and glaucoma |
| Q36167529 | Optical Coherence Tomography Features in Diabetic Macular Edema and the Impact on Anti-VEGF Response |
| Q24186424 | Optical coherence tomography (OCT) for detection of macular oedema in patients with diabetic retinopathy |
| Q24235325 | Optical coherence tomography (OCT) for detection of macular oedema in patients with diabetic retinopathy |
| Q35205992 | Optical coherence tomography-guided selective focal laser photocoagulation: a novel laser protocol for diabetic macular edema |
| Q64882207 | Out of darkness comes light-is there a role for light masks in treatment of diabetic macular oedema? |
| Q39941359 | Outcomes of intravitreal anti-VEGF therapy in eyes with both neovascular age-related macular degeneration and diabetic retinopathy |
| Q39269643 | Oxidative stress and diabetic retinopathy: development and treatment |
| Q34501650 | Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial |
| Q33949871 | Panretinal photocoagulation (PRP) versus PRP plus intravitreal ranibizumab for high-risk proliferative diabetic retinopathy |
| Q34528134 | Pathophysiology and treatment of diabetic retinopathy |
| Q38372446 | Patients' preferences for involvement in the decision-making process for treating diabetic retinopathy |
| Q48021083 | Patterns of retinal thickness prior to and following treatment with fluocinolone acetonide 190 µg intravitreal implant for diabetic macular edema |
| Q41789955 | Peripapillary nerve fiber layer thickness changes after macular photocoagulation for clinically significant diabetic macular edema |
| Q35889168 | Persistent Macular Thickening After Ranibizumab Treatment for Diabetic Macular Edema With Vision Impairment |
| Q50215366 | Persistent Macular Thickening Following Intravitreous Aflibercept, Bevacizumab, or Ranibizumab for Central-Involved Diabetic Macular Edema With Vision Impairment: A Secondary Analysis of a Randomized Clinical Trial. |
| Q41091625 | Persistent suppression of ocular neovascularization with intravitreal administration of AAVrh.10 coding for bevacizumab |
| Q26786012 | Perspective on the role of Ozurdex (dexamethasone intravitreal implant) in the management of diabetic macular oedema |
| Q35173079 | Pharmacokinetic evaluation of pegaptanib octasodium for the treatment of diabetic edema |
| Q58697579 | Pharmacological Management of Diabetic Macular Edema in Real-Life Observational Studies |
| Q39645541 | Physician-Industry Interactions and Anti-Vascular Endothelial Growth Factor Use Among US Ophthalmologists |
| Q85668055 | Planned foveal detachment technique for the resolution of diffuse diabetic macular edema |
| Q36104687 | Plasma Kallikrein-Kinin System as a VEGF-Independent Mediator of Diabetic Macular Edema |
| Q35797036 | Plasma kallikrein mediates retinal vascular dysfunction and induces retinal thickening in diabetic rats |
| Q90635817 | Plume Sign in the Deturgescence of Macular Cysts - A Novel OCT Finding |
| Q36977005 | Predicted impact of extending the screening interval for diabetic retinopathy: the Scottish Diabetic Retinopathy Screening programme |
| Q38845769 | Predicting outcomes to anti-vascular endothelial growth factor (VEGF) therapy in diabetic macular oedema: a review of the literature. |
| Q68641918 | Prediction of Anti-VEGF Response in Diabetic Macular Edema After 1 Injection |
| Q35221188 | Prediction, by retinal location, of the onset of diabetic edema in patients with nonproliferative diabetic retinopathy |
| Q64268367 | Predictor of Early Remission of Diabetic Macular Edema under As-Needed Intravitreal Ranibizumab |
| Q36763152 | Prospective study of inflammatory biomarkers and risk of diabetic retinopathy in the diabetes control and complications trial |
| Q39222559 | Protective effects of Lingguizhugan decoction on amyloid-beta peptide (25-35)-induced cell injury: Anti-inflammatory effects |
| Q35976653 | Protein kinase cβ phosphorylates occludin regulating tight junction trafficking in vascular endothelial growth factor-induced permeability in vivo |
| Q90311340 | Proteomic Biomarkers of Retinal Inflammation in Diabetic Retinopathy |
| Q35649867 | RANIBIZUMAB PLUS PROMPT OR DEFERRED LASER FOR DIABETIC MACULAR EDEMA IN EYES WITH VITRECTOMY BEFORE ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY. |
| Q91387329 | Randomised trial of wide-field guided PRP for diabetic macular oedema treated with ranibizumab |
| Q34440571 | Randomized clinical trial evaluating intravitreal ranibizumab or saline for vitreous hemorrhage from proliferative diabetic retinopathy |
| Q35054240 | Randomized clinical trials in diabetic macular edema |
| Q33843242 | Randomized trial evaluating short-term effects of intravitreal ranibizumab or triamcinolone acetonide on macular edema after focal/grid laser for diabetic macular edema in eyes also receiving panretinal photocoagulation |
| Q41939283 | Ranibizumab for Visual Impairment due to Diabetic Macular Edema: Real-World Evidence in the Italian Population (PRIDE Study). |
| Q88312497 | Ranibizumab in Diabetic Macular Oedema - A Benefit-risk Analysis of Ranibizumab 0.5 mg PRN Versus Laser Treatment |
| Q37417759 | Ranibizumab in diabetic macular edema |
| Q36615673 | Ranibizumab in patients with dense cataract and proliferative diabetic retinopathy with rubeosis |
| Q39292954 | Ranibizumab in the Treatment of Diabetic Macular Edema: A Review of the Current Status, Unmet Needs, and Emerging Challenges |
| Q34037627 | Ranibizumab in the treatment of patients with visual impairment due to diabetic macular edema. |
| Q35534298 | Ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema: a meta-analysis of randomized controlled trials |
| Q34410824 | Ranibizumab, verteporfin photodynamic therapy or observation for the treatment of myopic choroidal neovascularization: cost effectiveness in the UK. |
| Q34166795 | Ranibizumab: in diabetic macular oedema |
| Q33659440 | Rates of referable eye disease in the Scottish National Diabetic Retinopathy Screening Programme. |
| Q34089742 | Rationale for the diabetic retinopathy clinical research network treatment protocol for center-involved diabetic macular edema |
| Q42835669 | Re: Changing Trends in the Management of Diabetic Macular Edema at a Single Institution Over the Past Decade |
| Q90975604 | Real-world management and long-term outcomes of diabetic macular oedema with good visual acuity |
| Q64911569 | Real-world outcomes of observation and treatment in diabetic macular edema with very good visual acuity: the OBTAIN study. |
| Q35935370 | Recent advancements in diabetic retinopathy treatment from the Diabetic Retinopathy Clinical Research Network |
| Q47168388 | Recent advances in the management and understanding of diabetic retinopathy |
| Q28084139 | Recent developments in laser treatment of diabetic retinopathy |
| Q39171694 | Recognising and managing diabetic retinopathy |
| Q37968572 | Regenerative nanomedicine and the treatment of degenerative retinal diseases |
| Q35603578 | Regression of early diabetic macular oedema is associated with prevention of dark adaptation |
| Q33563100 | Relation between macular morphology and treatment frequency during twelve months with ranibizumab for diabetic macular edema |
| Q44043489 | Relationship between diabetic retinopathy, diabetic macular oedema and erectile dysfunction in type 2 diabetics |
| Q92003416 | Relationship between duration and extent of oedema and visual acuity outcome with ranibizumab in diabetic macular oedema: A post hoc analysis of Protocol I data |
| Q64907150 | Repeatability and reproducibility of retinal and choroidal thickness measurements in Diabetic Macular Edema using Swept-source Optical Coherence Tomography. |
| Q35568276 | Repeated intravitreous ranibizumab injections for diabetic macular edema and the risk of sustained elevation of intraocular pressure or the need for ocular hypotensive treatment |
| Q95410568 | Reply |
| Q39010176 | Report of 12-months efficacy and safety of intravitreal fluocinolone acetonide implant for the treatment of chronic diabetic macular oedema: a real-world result in the United Kingdom |
| Q35012475 | Reproducibility of Optovue RTVue Optical Coherence Tomography Retinal Thickness Measurements and Conversion to Equivalent Zeiss Stratus Metrics in Diabetic Macular Edema |
| Q35198501 | Reproducibility of spectral-domain optical coherence tomography retinal thickness measurements and conversion to equivalent time-domain metrics in diabetic macular edema |
| Q38002135 | Retinal neuropathy precedes vasculopathy in diabetes: a function-based opportunity for early treatment intervention? |
| Q37122850 | Retinal not systemic oxidative and inflammatory stress correlated with VEGF expression in rodent models of insulin resistance and diabetes |
| Q42367664 | Reversible retinal vessel closure from VEGF-induced leukocyte plugging |
| Q92594491 | Role of Inflammation in Classification of Diabetic Macular Edema by Optical Coherence Tomography |
| Q33730079 | Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study |
| Q59808570 | Safety of high-dose intravitreal triamcinolone acetonide as low-cost alternative to anti-vascular endothelial growth factor agents in lower-middle-income countries |
| Q36093262 | Safety, tolerability, and bioavailability of topical SAR 1118, a novel antagonist of lymphocyte function-associated antigen-1: a phase 1b study |
| Q38021421 | Screening for diabetic retinopathy and diabetic macular edema in the United Kingdom |
| Q38130162 | Screening, prevention, and ambitious management of diabetic macular edema in patients with type 1 diabetes |
| Q42126619 | Short-term Efficacy of Intravitreal Dexamethasone Implant in Vitrectomized Eyes with Recalcitrant Diabetic Macular Edema and Prior Anti-VEGF Therapy |
| Q36307731 | Short-term effects of intravitreal ranibizumab therapy on diabetic macular edema |
| Q35344194 | Side-effects and complications of laser treatment in diabetic retinal disease |
| Q38104680 | Soluble mediators of diabetic macular edema: the diagnostic role of aqueous VEGF and cytokine levels in diabetic macular edema |
| Q38963936 | Steroid-induced ocular hypertension/glaucoma: Focus on pharmacogenomics and implications for precision medicine |
| Q41393449 | Strategy for the management of diabetic macular edema: the European vitreo-retinal society macular edema study. |
| Q34980970 | Structural and functional measures of efficacy in response to bevacizumab monotherapy in diabetic macular oedema: exploratory analyses of the BOLT study (report 4). |
| Q38145185 | Structural changes in individual retinal layers in diabetic macular edema |
| Q38964388 | Sub-Tenon Injections of Triamcinolone Acetonide Had Limited Effect on Cystoid Macular Edema Secondary to Nanoparticle Albumin-Bound-Paclitaxel (Abraxane). |
| Q35147159 | Subthreshold diode-laser micropulse photocoagulation as a primary and secondary line of treatment in management of diabetic macular edema |
| Q90141414 | Surgical Innovations in the Treatment of Diabetic Macular Edema and Diabetic Retinopathy |
| Q38177288 | Surgical treatment for macular edema |
| Q28817495 | Sustained inflammation after pericyte depletion induces irreversible blood-retina barrier breakdown |
| Q89531841 | Sustained treatment of retinal vascular diseases with self-aggregating sunitinib microparticles |
| Q50872004 | Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema. |
| Q34062494 | Switching to less expensive blindness drug could save medicare part B $18 billion over a ten-year period |
| Q26823985 | Systematic review and mixed treatment comparison of intravitreal aflibercept with other therapies for diabetic macular edema (DME) |
| Q91842400 | Systemic Factors Associated with Treatment Response in Diabetic Macular Edema |
| Q38630749 | TREATMENT PATTERNS AND 2-YEAR VISION OUTCOMES WITH BEVACIZUMAB IN DIABETIC MACULAR EDEMA: An Analysis From a Large U.S. Integrated Health Care System |
| Q46407140 | Ten years of anti-vascular endothelial growth factor therapy |
| Q37510708 | The Anti-VEGF Epidemic: What are the Implications for Glaucoma Services? |
| Q38902223 | The Efficacy and Safety of Current Treatments in Diabetic Macular Edema: A Systematic Review and Network Meta-Analysis |
| Q90409273 | The Evolving Treatment of Diabetic Retinopathy |
| Q42920003 | The Optic UK Lecture: bench-to-bedside adventures of a diabetes researcher: results past, results present |
| Q55078881 | The RELATION study: efficacy and safety of ranibizumab combined with laser photocoagulation treatment versus laser monotherapy in NPDR and PDR patients with diabetic macular oedema. |
| Q47099972 | The Role of Focal Laser in the Anti-Vascular Endothelial Growth Factor Era. |
| Q35950857 | The Role of Plasma Kallikrein-Kinin Pathway in the Development of Diabetic Retinopathy: Pathophysiology and Therapeutic Approaches |
| Q39103989 | The United Kingdom Diabetic Retinopathy Electronic Medical Record Users Group, Report 1: baseline characteristics and visual acuity outcomes in eyes treated with intravitreal injections of ranibizumab for diabetic macular oedema. |
| Q26783404 | The Vitreomacular Interface in Diabetic Retinopathy |
| Q26783575 | The clinical utility of aflibercept for diabetic macular edema |
| Q35947430 | The combination of phacoemulsification surgery and intravitreal triamcinolone injection in patients with cataract and diabetic macular edema |
| Q55087230 | The development of a reference database with the Topcon 3D OCT-1 Maestro. |
| Q36425846 | The effect of intravitreal vascular endothelial growth factor on inner retinal oxygen delivery and metabolism in rats |
| Q90197758 | The impact of artificial intelligence in the diagnosis and management of glaucoma |
| Q34957921 | The management of diabetic macular oedema |
| Q34149599 | The pathogenesis of early retinal changes of diabetic retinopathy |
| Q34220590 | The potential of nanomedicine therapies to treat neovascular disease in the retina. |
| Q51165637 | The primary care physician's role in preventing vision loss and blindness in patients with diabetes. |
| Q34378757 | The relative clinical effectiveness of ranibizumab and bevacizumab in diabetic macular oedema: an indirect comparison in a systematic review |
| Q26798348 | The role of aflibercept in the management of diabetic macular edema |
| Q84789086 | The role of macular hydration in the evaluation of the effect of intravitreal triamcinolone on visual acuity in eyes with diabetic macular edema |
| Q26849299 | The therapeutic potential of intraocular depot steroid systems: developments aimed at prolonging duration of efficacy |
| Q36280656 | Therapeutic Options in Refractory Diabetic Macular Oedema |
| Q43522930 | Three-dimensional imaging of the inner limiting membrane folding on the vitreomacular interface in diabetic macular edema |
| Q45335472 | Time required for navigated macular laser photocoagulation treatment with the Navilas |
| Q53412660 | Topical dexamethasone γ-cyclodextrin nanoparticle eye drops increase visual acuity and decrease macular thickness in diabetic macular oedema. |
| Q36573796 | Topical pazopanib blocks VEGF-induced vascular leakage and neovascularization in the mouse retina but is ineffective in the rabbit |
| Q90754697 | Translating evidence into practice: recommendations by a UK expert panel on the use of aflibercept in diabetic macular oedema |
| Q37806321 | Treatment of diabetic retinopathy with anti-VEGF drugs |
| Q59126156 | Treatment patterns in diabetic macular edema in Taiwan: a retrospective chart review |
| Q35870506 | Treatment strategies for refractory diabetic macular edema: switching anti-VEGF treatments, adopting corticosteroid-based treatments, and combination therapy |
| Q35933773 | Trends in the Care of Diabetic Macular Edema: Analysis of a National Cohort |
| Q34213181 | Triple therapy: Phaco-vitrectomy with ILM peeling, retinal endophotocoagulation, and intraoperative use of bevacizumab for diffuse diabetic macular edema. |
| Q42150402 | Two year result of intravitreal bevacizumab for diabetic macular edema using treat and extend protocol |
| Q36167145 | Two-wavelength fundus autofluorescence and macular pigment optical density imaging in diabetic macular oedema. |
| Q57300760 | Ultra-wide optical coherence tomography angiography in diabetic retinopathy |
| Q33790255 | Upcoming therapeutic advances in diabetic macular edema: an intravitreal dexamethasone drug delivery system |
| Q28074846 | Update on corticosteroids for diabetic macular edema |
| Q36371395 | Update on risk of endophthalmitis after intravitreal drug injections and potential impact of elimination of topical antibiotics |
| Q35578747 | Updates in the management of diabetic macular edema |
| Q26767100 | Updates on the Clinical Trials in Diabetic Macular Edema |
| Q92860697 | Ursodeoxycholic Acid Attenuates the Retinal Vascular Abnormalities in Anti-PDGFR-β Antibody-Induced Pericyte Depletion Mouse Models |
| Q47243737 | VEGF-A gene polymorphisms and responses to intravitreal ranibizumab treatment in patients with diabetic macular edema. |
| Q34518374 | VEGF: From Discovery to Therapy: The Champalimaud Award Lecture. |
| Q34869372 | Validity of self-report in type 1 diabetic subjects for laser treatment of retinopathy |
| Q30244247 | Vascular Endothelial Growth Factor Inhibitors for Diabetic Retinopathy |
| Q36338786 | Vascular Safety of Ranibizumab in Patients With Diabetic Macular Edema: A Pooled Analysis of Patient-Level Data From Randomized Clinical Trials |
| Q38153731 | Vascular endothelial growth factor gene polymorphisms and vitreous proteome changes in diabetic retinopathy |
| Q38829399 | Viewing the choroid: where we stand, challenges and contradictions in diabetic retinopathy and diabetic macular oedema. |
| Q96305369 | Visual and anatomic outcomes of sustained single agent anti-VEGF treatment versus double anti-VEGF switching in the treatment of persistent diabetic macular edema |
| Q37772801 | Visual dysfunction associated with diabetic retinopathy |
| Q48268398 | Visual improvement following continuous positive airway pressure therapy in diabetic subjects with clinically significant macular oedema and obstructive sleep apnoea: proof of principle study. |
| Q36203135 | Visual outcome of laser treatment in diabetic macular edema: Study from an Urban Diabetes Care Center |
| Q34752779 | Vitrectomy combined with intravitreal triamcinolone acetonide injection and macular laser photocoagulation for nontractional diabetic macular edema |
| Q40918766 | Vitrectomy for center-involved diabetic macular edema |
| Q47166322 | Vitreoretinal interface abnormalities in diabetic macular edema and effectiveness of anti-VEGF therapy: an optical coherence tomography study |
| Q37719142 | Vitreoretinal interface abnormalities in patients treatedwith ranibizumab for diabetic macular oedema |
| Q83907682 | [Diabetic retinopathy and maculopathy] |
| Q85725384 | [Diagnosis, therapy and follow up of diabetic eye disease] |
| Q36257726 | β2-Adrenergic Receptor Antagonism Attenuates CNV Through Inhibition of VEGF and IL-6 Expression |
Search more.